RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Prostate Cancer · CDK12 Gene Mutation

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Haitao Wang) · peterrock2000@126.com · +86-02288326610
Contact: Study coordinator (Lili Wang) · wangliliaigang@163.com · +86-13516108466
Contact: Principal Investigator (Haitao Wang)
Lili Wang (Sub-investigator)
Dingkun Hou (Sub-investigator)
Jinhuan Wang (Sub-investigator)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · El Paso, United States

A Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Wuhan, China

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chengdu, China · Tianjin, China